China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese… Read more
Market Cap & Net Worth: China Resources Pharmaceutical Group Limited (640)
China Resources Pharmaceutical Group Limited (F:640) has a market capitalization of $3.21 Billion (€3.13 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #7589 globally and #806 in its home market, demonstrating a 4.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China Resources Pharmaceutical Group Limited's stock price €0.50 by its total outstanding shares 6282510461 (6.28 Billion).
China Resources Pharmaceutical Group Limited Market Cap History: 2016 to 2026
China Resources Pharmaceutical Group Limited's market capitalization history from 2016 to 2026. Data shows growth from $851.24 Million to $3.21 Billion (15.71% CAGR).
China Resources Pharmaceutical Group Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China Resources Pharmaceutical Group Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
China Resources Pharmaceutical Group Limited's market cap is 0.02 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.30x
China Resources Pharmaceutical Group Limited's market cap is 1.30 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $851.24 Million | $156.71 Billion | $2.82 Billion | 0.01x | 0.30x |
| 2017 | $951.20 Million | $172.53 Billion | $3.48 Billion | 0.01x | 0.27x |
| 2018 | $1.13 Billion | $189.69 Billion | $4.04 Billion | 0.01x | 0.28x |
| 2019 | $898.97 Million | $204.45 Billion | $3.29 Billion | 0.00x | 0.27x |
| 2020 | $728.72 Million | $200.42 Billion | $3.30 Billion | 0.00x | 0.22x |
| 2021 | $845.44 Million | $236.81 Billion | $3.77 Billion | 0.00x | 0.22x |
| 2022 | $2.51 Billion | $254.11 Billion | $4.15 Billion | 0.01x | 0.61x |
| 2023 | $2.36 Billion | $244.70 Billion | $3.85 Billion | 0.01x | 0.61x |
| 2024 | $4.35 Billion | $257.67 Billion | $3.35 Billion | 0.02x | 1.30x |
Competitor Companies of 640 by Market Capitalization
Companies near China Resources Pharmaceutical Group Limited in the global market cap rankings as of March 18, 2026.
Key companies related to China Resources Pharmaceutical Group Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
China Resources Pharmaceutical Group Limited Historical Marketcap From 2016 to 2026
Between 2016 and today, China Resources Pharmaceutical Group Limited's market cap moved from $851.24 Million to $ 3.21 Billion, with a yearly change of 15.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.21 Billion | +4.62% |
| 2025 | €3.07 Billion | -29.48% |
| 2024 | €4.35 Billion | +84.78% |
| 2023 | €2.36 Billion | -6.12% |
| 2022 | €2.51 Billion | +196.80% |
| 2021 | €845.44 Million | +16.02% |
| 2020 | €728.72 Million | -18.94% |
| 2019 | €898.97 Million | -20.11% |
| 2018 | €1.13 Billion | +18.31% |
| 2017 | €951.20 Million | +11.74% |
| 2016 | €851.24 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of China Resources Pharmaceutical Group Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.21 Billion USD |
| MoneyControl | $3.21 Billion USD |
| MarketWatch | $3.21 Billion USD |
| marketcap.company | $3.21 Billion USD |
| Reuters | $3.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.